Dyne Therapeutics, Inc. (DYN)
Market Cap | 700.91M |
Revenue (ttm) | n/a |
Net Income (ttm) | -208.13M |
Shares Out | 61.38M |
EPS (ttm) | -3.58 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 428,385 |
Open | 11.50 |
Previous Close | 11.42 |
Day's Range | 11.18 - 11.61 |
52-Week Range | 6.40 - 15.60 |
Beta | 0.79 |
Analysts | Strong Buy |
Price Target | 27.20 (+135.29%) |
Earnings Date | Oct 30, 2023 |
About DYN
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachuset... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for DYN stock is "Strong Buy." The 12-month stock price forecast is $27.2, which is an increase of 135.29% from the latest price.
News

Dyne Therapeutics to Present at November Investor Conferences
WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peop...

Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones
- Initial ACHIEVE and DELIVER Data to be Presented at a Company Event Around the J.P. Morgan Healthcare Conference in Early January 2024, Including Safety, Biomarker of Splicing and Functional Outcome...

Dyne Therapeutics to Present at October Investor Conferences
WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peo...

Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
- On Track to Report Initial Data from the Global, Multiple Ascending Dose Phase 1/2 ACHIEVE Clinical Trial in the Second Half of 2023 -

Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peo...

Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
- On Track to Report Initial Data from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD During the Second Half of 2023 -

Dyne Therapeutics to Present at Jefferies Healthcare Conference
WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peop...

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101
- Initial Data from Global, Multiple Ascending Dose Phase 1/2 ACHIEVE Clinical Trial in Myotonic Dystrophy Type 1 Anticipated in the Second Half of 2023 -

Dyne Therapeutics' Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting
- Broad Distribution in CNS Demonstrated in Non-Human Primates - - Achieved Reduction of Toxic Nuclear DMPK RNA and Foci in the Brain in a DM1 Disease Model - WALTHAM, Mass., May 17, 2023 (GLOBE NEWSW...

Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
- On Track to Report Initial Data from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD During the Second Half of 2023 -

Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference
WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peopl...

Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS
- FORCE Delivers to CNS in Non-Human Primates - - FORCE Achieves Robust Reduction of Toxic Nuclear DMPK RNA and Foci in Brain of a DM1 Disease Model -

Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
- Data from the Global, Multiple Ascending Dose Phase 1/2 DELIVER Clinical Trial Anticipated in the Second Half of 2023 -

Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference
- Company Presents Overviews of ACHIEVE and DELIVER Global Clinical Trials with Data Anticipated from Both Studies in the Second Half of 2023 -

Dyne Therapeutics to Present at Upcoming Investor Conferences
WALTHAM, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peo...

Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
- Data Anticipated in the Second Half of 2023 from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD -

Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peop...

Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
- DYNE-101 ACHIEVE and DYNE-251 DELIVER Clinical Trials Underway with Data Anticipated in the Second Half of 2023 -

Dyne Therapeutics to Present at Investor Conferences in November
WALTHAM, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peop...

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
- Company Anticipates Reporting Data from Global, Multiple Ascending Dose DELIVER Clinical Trial in the Second Half of 2023 -

Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress
- Poster Highlights In Vivo Data for DYNE-251, Now Being Evaluated in Phase 1/2 DELIVER Clinical Trial in Patients Amenable to Exon 51 Skipping - - First Presentation of In Vitro Data for FORCE™ Plat...

Dyne Therapeutics to Present at Chardan's 6th Annual Genetic Medicines Conference
WALTHAM, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peo...

Dyne Therapeutics Highlights DM1 and DMD Clinical Programs During “Spotlight on the Clinic” Virtual Event
- Presentation and Discussion with Two Leading Neuromuscular Disease Experts -

Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peo...

Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
- First Patient Expected to be Dosed in September -